Diabetes is a growing global health challenge. Although insulin therapy has advanced significantly over the years, long-term diabetes-associated complications remain a major concern and may be better addressed through cell-based therapies. We are developing next-generation methods to generate insulin producing cells (organoid-derived β-like cells) as a scalable and robust source for cell replacement therapy.
reNEW research
Organoids are miniature, lab-grown models derived from stem cells that enable scientists to understand how organs develop and explore new approaches for repairing or replacing damaged cells. We are developing a new generation of improved pancreatic organoids using precisely timed periods of enhanced cell expansion to generate more mature and functionally improved organoid-derived β-like cells. This innovative system has promising applications in regenerative medicine, developmental biology, and drug screening.
Image description
A pancreatic organoid with groups of developing endocrine cells in magenta and the cellular cytoskeleton in green.
Credits
Dr. Ulla-Maj Fiuza, Postdoc, Brickman lab, reNEW Copenhagen.
